4th Dermatology Drug Development Summit Europe

The success of the dermatology industry in 2022, with approvals for Alopecia Areata and Vitiligo, brings new opportunity for dermatology drug development. These approvals highlight remaining unmet and treatable needs within dermatological diseases across rarer, autoimmune and genetic skin diseases.

The 4th Dermatology Drug Development Summit Europe provides you the tools to tackle the next dermatological opportunity, progressing existing treatments and developing successful therapies for the rarer dermatological diseases in addition to our arsenal against Atopic Dermatitis and Psoriasis.

View the full event guide here.

Join 80+ industry colleagues including the CEO, VPs, Heads and Directors of Dermatology from leading pharma and the pioneering biotechs to discuss how to navigate the most pressing challenges in dermatological drug development.

If you and your team are committed to advancing development in dermatological diseases, this is this summit is for you. Want to see more? View the official event guide for more information.